

# HEALTHCARE MONTHLY

FEBRUARY 2022

*Our healthcare team architects market-defining outcomes for some of the world's most innovative medical device, life science, diagnostics, healthcare services and pharmaceutical companies*












BioTech / Pharma

Healthcare Services

Life Sciences / Diagnostics


Medical Devices

## HEADLINE TRANSACTIONS


	TARGET	ACQUIROR	ACQUISITION SYNOPSIS
Life Sciences / Diagnostics	 		<ul style="list-style-type: none"> <li>TM Capital served as exclusive financial advisor to Quantib B.V. in connection with its sale to RadNet (NasdaqGM:RDNT)</li> <li>RadNet provides outpatient diagnostic imaging services in the United States including MRI, CT, PET, nuclear medicine, and other related procedures</li> <li>Quantib is a leading radiology AI and machine learning company focusing on clinical solutions for prostate cancer, breast cancer and neurodegeneration</li> </ul>
Medical Devices			<ul style="list-style-type: none"> <li>Owens &amp; Minor (NYSE:OMI) entered into a definitive agreement to acquire Apria (NasdaqGS:APR)</li> <li>Owens &amp; Minor is a healthcare distributor focusing on a variety of products including branded and proprietary products as well as medical-surgical products</li> <li>Apria provides integrated home healthcare equipment and related services</li> <li>Total Consideration: \$1.4 billion in cash, representing an enterprise value of \$1.7 billion</li> <li>Implied Enterprise Value: 1.5x LTM Revenue, 7.4x LTM EBITDA (26% premium)</li> </ul>
	  <small>Baring Private Equity Asia</small>		<ul style="list-style-type: none"> <li>Blackstone (NYSE:BX) acquired Interplex Holdings from Baring Private Equity</li> <li>Blackstone is a global multi-strategy investment firm with more than \$731 billion AUM</li> <li>Interplex designs, manufactures, and sells mission-critical customized interconnects, sensor solutions and specialized high precision products for the automotive, medical and life sciences, datacom and telecom and industrial products industries</li> <li>Enterprise Value: \$1.6 billion</li> </ul>
	 		<ul style="list-style-type: none"> <li>TPG Capital acquired a majority stake in Confluent Medical Technologies from Ampersand Capital Partners</li> <li>TPG is a multi-strategy global investment firm with more than \$109 billion AUM</li> <li>Confluent Medical Technologies operates as a contract manufacturer of nitinol-based components, balloon components, guidewires, and balloon catheters for medical device companies</li> </ul>

# HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins\*



\*EBITDA Margins shown as the gray line.

LTM Stock Price Index



# SELECTED HEALTHCARE TRANSACTIONS


Target	Acquiror	BioTech / Pharma Transactions
Zogenix (NasdaqGM:ZGNX)	UCB BioSciences (ENXTBR:UCB)	Zogenix develops therapies for patients living with rare diseases in the United States Total Consideration: \$1.5 billion in cash and \$300 million in earnout contingencies (72% premium)
Exelead, Inc.	Merck Group (XTRA:MRK)	Exelead manufactures various pharmaceutical products including lipid nanoparticle, liposome, and pegylation formulations Total Consideration: \$780 million in cash
Triad Life Sciences, Inc.	Convatec Group Plc (LSE:CTEC)	Triad Life Sciences develops bioactive tissue-based materials and therapies to treat acute and chronic wounds, soft tissue injuries, and other regenerative applications Total Consideration: \$125 million in cash and \$325 million in earnout contingencies

Target	Acquiror	Life Sci / Diagnostics Transactions
GeneDx, Inc.	Sema4 Holdings Corp. (NasdaqGS:SMFR)	GeneDx offers clinical genetic exome sequencing for the detection of diseases such as hereditary cancers, gene diseases and neurological disorders Total Consideration: \$473 million in cash and stock and \$150 million in earnout contingencies
MyChem, LLC	TriLink BioTechnologies, Inc.	MyChem develops ultra-pure nucleotides, modified nucleotides and dye labeled nucleotides Total Consideration: \$240 million in cash
PreventionGenetics LLC	Exact Sciences Corporation (NasdaqCM:EXAS)	PreventionGenetics provides clinical DNA testing, DNA banking, and research genotyping services Total Consideration: \$190 million in cash

Target	Acquiror	Health Services Transactions
Cloudmed	R1 RCM (NasdaqGS:RCM)	Cloudmed partners with over 3,100 healthcare providers in the United States and recovers over \$1.5 billion annually of underpaid or unidentified revenue for its clients by using its proprietary Cloudmed AI platform Total Consideration: \$3.2 billion in stock and \$850 million in assumed liabilities
Castlight Health, Inc. (NYSE:CSLT)	Vera Whole Health Inc.	CastLight provides digital health navigation solutions for employers and health plan participants Total Consideration: \$370 million in cash (25% premium)
Alpaca Audiology, LLC	Sonova Holding AG (SWX:SOON)	Alpaca Audiology distributes audiology products to clinics and operates a network of nationwide audiology clinics Total Consideration: \$310 million in cash

Target	Acquiror	Medical Device Transactions
Afera, Inc.	Medtronic plc (NYSE:MDT)	Afera develops cardiac arrhythmia treatment solutions Total Consideration: \$675 million in cash representing a \$925 million enterprise value
Suneva Medical, Inc.	Viveon Health Acquisition Corp. (NYSEAM:VHAQ)	Suneva Medical develops and manufactures products for general dermatology and aesthetic markets including fat grafting, platelet-rich plasma treatments and dermal fillers Total Consideration: \$370 million in cash and stock
Engage Surgical	Smith & Nephew plc (LSE:SN)	Engage Surgical provides a knee replacement system called Engage Partial Knee System

## Selected TM Capital Healthcare Experience



A PORTFOLIO COMPANY OF  
**HOLLAND CAPITAL**  
HAS BEEN ACQUIRED BY  
**RadNet**



HAS RECEIVED A STRATEGIC INVESTMENT FROM  
**CATHAY CAPITAL**  
凯辉基金



HAS BEEN ACQUIRED BY  
**TRAJAN**

## TM Capital's Healthcare Industry Contacts



**James McLaren**  
Managing Director  
jmclaren@tmcapital.com  
212.809.1414



**Michael Goldman**  
Managing Director  
mgoldman@tmcapital.com  
212.809.1419



**Paul Smolevitz**  
Managing Director  
psmolevitz@tmcapital.com  
212.809.1416



**John Dean**  
Principal  
jdean@tmcapital.com  
404.995.6234



**Steve Hunter**  
Managing Director, Sponsor Coverage  
shunter@tmcapital.com  
404.995.6232